Key result
Pharmacist-provider collaborative care linked to ~2-fold higher IV iron guideline adherence vs. usual care.
Why the study?
Only one-fifth of patients meeting criteria for IV iron receive it in real-world practice, prompting evaluation of a pharmacists-providers collaborative clinic to implement guideline-directed therapy.
Does a multidisciplinary pharmacists-providers collaborative iron deficiency clinic improve adherence to appropriate intravenous iron use criteria, laboratory monitoring, and dosing compared to usual care in patients with heart failure or pulmonary hypertension?
Cohort (n=187)
No
Does a multidisciplinary pharmacists-providers collaborative iron deficiency clinic improve adherence to appropriate intravenous iron use criteria, laboratory monitoring, and dosing compared to usual care in patients with heart failure or pulmonary hypertension?
A multidisciplinary pharmacists-providers collaborative iron deficiency clinic doubled adherence to guideline-directed intravenous iron dosing and laboratory monitoring (81.3% vs. 40%) in a rural heart failure population.
Answers are grounded in this paper and cite their sources.
Collaborative pharmacist care was associated with higher IV iron adherence in HF; extends pilot data but leaves open randomized outcome trials.
BACKGROUND: Only one-fifth of patients meeting the criteria for intravenous (IV) iron therapy received IV iron in the real-world practice. Pharmacists-providers collaborative iron deficiency (ID) clinic was developed to implement guideline-directed IV iron therapy. OBJECTIVE: To evaluate the 4-year performance of the pharmacists-providers collaborative ID treatment clinic in the heart failure (HF) service. METHODS: A single-center retrospective cohort study was conducted to evaluate the performance of the iron deficiency pharmacists-providers collaborative care clinic during the induction and maintenance phases of IV iron therapy. The study included patients who were seen by HF providers and received the IV iron consultation with HF pharmacists. The study included patients aged 18 years or older who were diagnosed with HF or pulmonary hypertension and received at least 1 dose of IV iron in outpatient settings. It was managed by the pharmacists-providers collaborative IV iron clinic. The primary outcome was adherence to all of the following criteria: the IV iron appropriate use criteria, laboratory requirements, and dosing during the induction course. The use of oral iron therapy was evaluated. RESULTS: A total of 187 patients were included in the final cohort. The median follow-up period of the IV iron consulting team was 372 (176, 623) days. One hundred fifty-two patients (81.3%) were adherent to the appropriate criteria. The most common reasons for nonadherence were the absence of maintenance laboratory requirements (15.5%), failure to administer all induction doses (1.6%), inappropriate use (1.1%), and incorrect dose (0.5%). Among 15 patients on oral iron therapy, the consulting team discontinued it in 3 patients (20.0%) during follow-up. CONCLUSION AND RELEVANCE: The pharmacists-providers collaborative IV iron clinic was effective to implement IV iron therapy in heart failure care settings. These results highlight the importance of multidisciplinary care management for ID in real-world HF practice.
No takes yet. Share an insight, caveat, or question.
Kido et al. (2026) conducted a cohort in Heart failure or pulmonary hypertension with iron deficiency (n=187). Pharmacists-providers collaborative iron deficiency clinic managing outpatient intravenous iron therapy (ferric carboxymaltose or iron sucrose) vs. Pre-implementation usual iron deficiency care group (n=42) was evaluated on Adherence to intravenous iron appropriate use criteria, laboratory requirements, and dosing during the induction course (p=<0.001). Pharmacist-provider collaborative care increased adherence to IV iron appropriate use, dosing, and monitoring criteria compared to usual care.
Synapse has enriched 10 related papers. Consider them for comparative context: